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Little is known about endogenous descending control of itch. In chronic pain, descending pain 3 
inhibition is reduced as signified by lowered conditioned pain modulation (CPM). There are 4 
indications that patients with chronic itch may also exhibit reduced endogenous descending 5 
inhibition of itch and pain. This study aimed to investigate whether and the extent to which itch 6 
can be modulated by conditioning itch and pain stimuli. Twenty-six healthy volunteers 7 
participated. The study consisted of 5 conditions designed to systematically assess endogenous 8 
modulation of itch or pain: 1) itch-induced modulation of contralateral itch, 2) pain-induced 9 
modulation of contralateral itch, 3) pain-induced modulation of ipsilateral itch, 4) pain-induced 10 
modulation of contralateral pain, and 5) itch-induced modulation of contralateral pain. 11 
Conditioning stimuli were cold pressor-induced pain and histamine-evoked itch, while the test 12 
stimuli were electrical stimulation paradigms designed to evoke itch or pain. Pain was 13 
significantly reduced (CPM-effect) by the conditioning pain stimulus (p<0.001), but not by the 14 
conditioning itch stimulus (negative control condition). Itch was significantly reduced (CIM-15 
effect) by both contra- and ipsilateral applied conditioning pain (both p<0.001), while 16 
conditioning itch stimulation only marginally reduced itch. Endogenous descending itch 17 
inhibition through mechanisms that are independent of segmental gating can be readily evoked 18 
by heterotopic conditioning pain stimulation. However, robust descending inhibition of itch 19 
cannot be evoked with itch conditioning stimulation. 20 
 21 
Perspective: The study shows a hierarchical prioritization favouring pain-induced central 22 
descending modulation of both itch and pain in humans. Future studies addressing potential 23 
aberrations in pain-evoked descending modulation of itch in chronic itch patients are warranted. 24 





Itch is an unpleasant sensory experience, distinct from pain, transmitted by two parallel 3 
nociceptive pathways: a subgroup of mechano-insensitive C-fibers transmit histaminergic itch 4 
and a subgroup of polymodal C-fibers transmit non-histaminergic itch36,59. After synapsing in the 5 
superficial spinal dorsal horn signalling is transmitted in the anterolateral tracts to areas 6 
including the thalamus, periaqueductal grey, and the parabrachial area46. Itch and pain share 7 
numerous of mechanistic similarities58. Notably, as for pain, itch is under strict segmental control 8 
as well as descending endogenous modulation12,18,48. In the spinal dorsal horn, inhibitory basic 9 
helix-loop-helix B5-interneurons (Bhlhb5), which are activated by painful stimuli, control 10 
pruriceptive transmission15,56. This can be quantified in humans by application of a homotopic 11 
nociceptive stimulus (e.g., scratching) to an itching skin area whereby the itch is transiently 12 
inhibited6,71. The dysesthesias that pain and itch are capable of inducing, and for both modalities 13 
thought to reflect central sensitization, are also alike58. Specifically, alloknesis (itch evoked by a 14 
stimulus not normally evoking itch) and hyperknesis (increased itch in response to stimuli 15 
normally evoking itch) are analogues to allodynia and hyperalgesia, respectively1,35.  16 
 17 
Conditioned pain modulation (CPM) is an endogenous centrally-mediated pain regulatory 18 
phenomenon occurring in humans, considered the perceptual correlate of diffuse noxious 19 
inhibitory controls (DNIC) established in animals8,67. In CPM-paradigms the pain evoked by a 20 
test stimulus can be reduced by applying a nociceptive conditioning stimulus to a location remote 21 
(i.e. heterotopically) from that of the test stimulus site51. Multiple parallel descending pain 22 
modulatory pathways exist, involving areas such as the medullary reticularis nucleus dorsalis, the 23 
rostral ventromedial medulla and the periaqueductal grey 45,53. CPM-efficacy has been shown to 24 
be impaired in a multitude of chronic pain conditions such as osteoarthritis, diabetic neuropathy, 25 
and fibromyalgia, when compared to healthy individuals38. Decreased CPM-efficacy has also 26 
been shown to predict the development of chronic post-operative pain69 as well as increased 27 
analgesic responsiveness to certain anti-depressant/convulsive drugs (suggested to restore 28 
endogenous pain inhibition70). Moreover, although evidence is limited and/or conflicting there 29 
are indications that individual psychological characteristics such as optimism, catastrophizing, 30 
and negative affectivity may be associated with CPM-efficacy17,22,34. 31 
 32 
Previous studies suggests that deranged endogenous sensory modulation and sensitization may 33 
play a role in maintaining or enhancing chronic itch in patients suffering common chronic itch 34 
conditions e.g., atopic dermatitis or psoriasis23,25,31–33. Such findings includes the lack of a good 35 
correlation between objective disease measures and experienced itch14, sensitization to itching 36 
and thermal stimuli25,27,63, decreased efficacy of homotopic counter-stimuli27, and reports of 37 
antipruritic effectiveness of drugs thought to enhance endogenous pain inhibition50. However, it 38 
is currently unclear whether a central endogenous modulation system akin to that involved in 39 
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CPM affects itch processing (i.e. conditioned itch modulation; CIM) and if so, which kinds of 1 
conditioning stimuli are required to activate it3,32,34.  2 
 3 
To examine the organization and efficacy of central pain- and itch-mediated endogenous 4 
descending modulation of itch in humans, this study aimed to investigate the effect of 5 
conditioning itch and conditioning pain stimuli on electrically evoked itch, primarily focusing on 6 
the mean levels of itch and pain and secondarily on the peak levels of itch and pain. In parallel, a 7 
standard CPM-paradigm acting as a positive comparator, and a condition assessing the potential 8 
effect of a conditioning itch stimulus on pain perception were conducted. We hypothesized that 9 
for pruriception; a descending inhibitory system parallel to that of the nociceptive system would 10 
exist. Exploratively, development of mechanical dysesthesias was monitored and individual 11 
characteristics of catastrophizing, optimism, and psychological distress were assessed. 12 
 13 
 14 






Twenty-eight healthy participants (14 males/14 females, mean age 23.0 years with standard 4 
deviation 2.8, range 18-29) were included. Recruitment took place at the campus of Aalborg 5 
University and via social media, with advertisements clearly displaying the criteria for 6 
participation. All participants gave written informed consent after being provided with written 7 
and verbal study information, and received a monetary compensation for participating. The study 8 
protocol was approved by the local Ethics Committee (N-20160026) and conducted in 9 
accordance with the Helsinki Declaration (World Medical Association, 2013). Inclusion criteria 10 
were being healthy, in the age group 18-65 years, and having a good understanding of English. 11 
Participants would have been rescheduled to a later moment if, in the 24 hours prior to testing, 12 
experiencing itch or pain >3 (on a scale from 0 to 10, ranging from no itch/pain to worst 13 
imaginable itch/pain), they had taken medication that could affect itch or pain sensitivity, e.g., 14 
antihistamines or analgesics or if they had consumed an excessive amount of alcohol (>5 units) 15 
or illicit drug. No participants had to be rescheduled. Two of the included participants had 16 
consumed medication deemed non-influential; an antibiotic for the treatment of intestinal 17 
parasites and an antidyslipidemic for hypercholesterolemia.  18 
 19 
Design 20 
The study had a within-subjects design. There were five randomized conditions; three 21 
investigating CIM and two investigating CPM. In each condition, first a baseline test stimulus 22 
(TS), and subsequently a simultaneous application of a test stimulus and a conditioning stimulus 23 
(TS+CS) was applied. Condition 1 (“CIM-itch”) consisted of an itch TS and a contralateral itch 24 
CS (see Table 1). Condition 2 (“CIM-pain”) consisted of an itch TS and a contralateral pain CS. 25 
Condition 3 (“CIM-painipsi”) consisted of an itch TS and an ipsilateral pain CS. Condition 4 26 
(“CPM-pain”) consisted of a pain TS and a contralateral pain CS. Condition 5 (“CPM-itch”) 27 
consisted of a pain TS and a contralateral itch CS. All stimuli were applied on the forearms and 28 
hands of the participants and a testing session lasted approximately 2 hours and 20 min per 29 
participant (See Figure 1). In a subsequent additional experiment, a CIM-itchsequential condition, 30 
i.e., with the TS applied after the CS, was tested based on findings of the first 5 conditions (see 31 
Additional experiment). Tests were conducted by a male (HHA) or female (AIMvL) 32 








<Insert Figure 1 about here> 41 
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  1 
Somatosensory stimuli and psychophysics 2 
 3 
Electrical test stimuli: All electrical stimuli were delivered by a constant current stimulator 4 
(Isolated Bipolar Constant Current Stimulator DS5, Digitimer, Hertfordshire, UK), controlled by 5 
a laptop via a data acquisition system (NI USB-6221 or NI-DAQmx, National Instruments, 6 
Austin, Tx, USA). The participants’ arms were prepared for electrical stimulation included 7 
scrubbing with NuPrep skin prep gel (Weaver and company, Aurora, Co, USA) and application 8 
of conductive gel (Spectra 360 electrode gel, Parker Laboratories Inc., Fairfield, NJ, USA). Tape 9 
(Transpore surgical tape 3M, St. Paul, MN, USA) was used to attach the electrodes. Electrical 10 
stimulation was chosen as test stimuli over other more physiological methods, such as cowhage 11 
or histamine provocations, because it permits: 1) accurate temporal control and 2) assessment of 12 
stimulus-response 1. 13 
Electrically evoked itch: For itch induction, two surface electrodes (disk electrode of 1 cm and 14 
reference electrode of 2 cm diameter, VCM Medical, Leusden, the Netherlands) were attached to 15 
the central volar surface of the forearm halfway the total forearm length (see Figure 2). In 16 
accordance to previous studies9,34, stimuli were applied at the volar side, at 50 Hz with a pulse 17 
duration of 100 µs, and at a continuously increasing current intensity of 0.05 mA/s. The current 18 
intensity of each itch stimulus started at 0.4 mA and ended at 6.4 mA, resulting in a ≈2 min 19 
duration per stimulus ramp.  20 
Electrically evoked pain: For pain induction, two surface electrodes (two disk electrodes of ø 1 21 
cm, VCM Medical, Leusden, the Netherlands) were attached to the central dorsal surface of the 22 
forearm halfway the total forearm length (see Figure 2). According to favourable pain-induction 23 
results from a previous study (van Laarhoven et al., unpublished), stimuli were applied at the 24 
dorsal side, at 50 Hz with a pulse duration of 400 µs. The stimulus intensity increased using a 25 
step-up paradigm, from 0.4 mA to 7.0 mA in 11 steps of 6 s each with 0.60 mA increment and a 26 
2 s interval in-between the steps, thus also resulting in a ≈2 min duration per stimulus step-up.  27 
 28 
Assessing electrically evoked itch and pain: Ratings of electrically induced itch and pain test 29 
stimuli were obtained during the electrical stimuli by using two electronic visual analogue scales 30 
(VASs) on a tablet (Galaxy Tab S2, Samsung, Seoul, South Korea) using a VAS application 31 
(Aalborg University, Aalborg, Denmark). A VAS for itch was displayed on top and a VAS for 32 
pain below, with anchors at the left end indicating no itch/pain (representing 0) and at the right 33 
end indicating worst imaginable itch/pain (representing 100). During all itch and pain test stimuli 34 
VAS ratings on both the itch and pain scale were continuously conducted and sampled once 35 
every 5 seconds.  36 
 37 
 38 





Conditioning itch stimulation: As itch CS, histamine (as dihydrochloride in a concentration of 2 
10 mg/ml, i.e. 1% EEAACI recommended positive control)4,16 was applied with 1-mm weight-3 
calibrated skin prick test lancets (SPT) using 120 g weight4. The SPTs were performed at the 4 
central volar forearms, 5 cm proximally from the cease of the wrist. A small drop of histamine 5 
was placed on the skin and percutaneously introduced with the SPT lancet11,20,72. 6 
Conditioning pain stimulation: To elicit pain as CS, a cold pressor task (CPT) was used with 7 
water of ca. 8 °C (mean 7.9 ± 0.1 and 8.3 ± 0.1 before and after CPT, respectively) in an 8 liter 8 
plastic box isolated by styrofoam. The water was circulated by an Anova Precision Cooker 9 
(Anova, San Francisco, California, USA) at a rate of 8 L/min. Participants were instructed to 10 
immerse their hand up to the level of their wrist into the water for the duration of the TS (i.e. ≈2 11 
min).  12 
 13 
Assessing conditioning itch and pain intensity: The perceived average intensity of evoked itch 14 
and pain by conditioning itch and pain stimulation were reported using two numeric rating scales 15 
(NRSs) from 0 (no itch or pain) to 10 (worst imaginable itch or pain). Ratings of the conditioning 16 
stimuli were conducted immediately after the 2 min test stimulus.  17 
 18 
Mechanical itch sensitivity: In between the two itch electrodes sensitivity to touch evoked itch 19 
(STI) was assessed using von Frey monofilaments (Stoelting, North Coast Medical, Gilroy, 20 
California, USA). Three monofilaments were applied: 4.08 mN, 4.17 mN, and 4.31 mN in 21 
consecutive order as previous described 2,6. The monofilaments were applied by pressing them 22 
onto the skin perpendicularly for 1 s until the filament bowed, after which the filament was 23 
gently lifted from the skin. Each filament was applied as triplicate. The participants indicated the 24 
average intensity of itch experienced following each of the triplicate stimulus application using 25 
the NRS from 0 to 10 for itch.  26 
 27 
Mechanical pain sensitivity: In between the two pain electrodes, mechanical pain sensitivity 28 
(MPS) was assessed using weight-calibrated pinprick stimulators with blunt tips (The PinPrick, 29 
MRC Systems GmbH, Heidelberg, Germany). Based on previous research indicating a 30 
mechanical pain threshold of ≈71 mN in healthy adult volunteers 55, the pins of 128 mN, 256 31 
mN, and 512 mN were selected to probe supra-threshold pain mechanical pain sensitivity. These 32 
pinprick stimulators were applied perpendicularly to the skin for 2s each in consecutive order, 33 
which procedure was repeated thrice, resulting in nine MPS assessments in each round. The 34 
participants indicated the average intensity of pain evoked by each pin-prick stimulus using the 35 
NRS from 0 to 10 for pain.  36 
 37 
Self-report questionnaires 38 
Based on previous research22 the following self-report questionnaires were administered in 39 
English. To keep the procedure across participants as comparable as possible and to allow 40 
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recruitment of non-Danish speakers, the experimental procedures were conducted in English 1 
regardless of whether HHA (Danish) or AIMvL (Dutch) was the active investigator. The Pain 2 
Catastrophizing Scale (PCS)64 was administered to assess catastrophizing of pain experienced in 3 
daily life. This questionnaire consists of 13 items, each rated on a Likert scale from 0 (not at all) 4 
to 4 (all the time). The total score was obtained by summing the scores for all items, with a 5 
theorectical range from 0 to 52. The Cronbach’s alpha in the present study was 0.88. The PCS 6 
was also administered in a for itch adjusted version (PCS-Itch), in which only the word “pain” 7 
for all items was substituted by the word “itch”. The Cronbach’s alpha of the PCS-Itch in the 8 
present study was 0.85. Dispositional optimism was measured with the revised Life Orientation 9 
Test (LOT-R)57, consisting of 3 positive, 3 negative, and 4 filler items which were rated on a 10 
Likert scale ranging from 1 (strongly disagree) to 5 (strongly agree). The total score can range 11 
from 0 to 24, with higher scores indicating higher optimism. Cronbach’s alpha was 0.75. The 12 
Hospital Anxiety and Depression Scale (HADS)73 was administered to assess psychological 13 
distress. This questionnaire consists of a subscale for depression (7 items; Cronbach’s alpha in 14 
the present study 0.62) and a subscale for anxiety (7 items Cronbach’s alpha in the present study 15 
0.61). Items were rated on a scale from 0 to 3, and the total scores for both subscales (each 16 
potentially ranging from 0 to 21) were obtained by summing the respective items with total 17 
scores.  18 
 19 
Procedure 20 
Upon arrival at the lab, participants were informed about the tests and fulfilment of inclusion and 21 
exclusion criteria were checked (see Figure 1 for the time line). Participants filled out the self-22 
report questionnaires before initiating the itch and pain inductions. Based on the hand dominancy 23 
of the participant, the side (dominant or non-dominant) of the itch and pain stimulation 24 
(contralaterally attached) was randomized using the randomly permuted block method 25 
(randomization.com) with separate lists for males and females. Before applying electrical 26 
stimuli, baseline mechanical sensitivity assessments were conducted, starting with either the 27 
assessments for itch (STI) or pain (MPS), determined by balanced randomization. Hereafter, in 28 
accordance to the order of the mechanical assessments, an electrical familiarization stimulus for 29 
either itch or pain was given, which participants perceived without rating the sensations. Then a 30 
similar electrical stimulus followed during which participants continuously rated the itch and 31 
pain levels using the electronic VAS. This procedure was then repeated for the other modality 32 
(e.g., when started with pain, itch stimuli were applied hereafter). Based on these stimuli, it was 33 
assessed whether the participant responded with adequate levels of itch or pain (pre-defined as a 34 
peak score of ≥20 on the intended modality). Further testing was terminated if participants were 35 
determined as non-responders for both stimulation modalities (i.e. peak VAS <20), which was 36 
the case for two participants, so the experiment was continued in 26 participants. CIM (1. CIM-37 
itch, 2. CIM-pain 3. CIM-painipsi) and CPM (4. CPM-pain, 5. CPM-itch) conditions were applied 38 
in a random order. Within each condition, a TS was applied first (i.e. baseline TS) followed by 39 
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the TS+CS. After each itch stimulus, STI was assessed and after each pain stimulus, MPS was 1 
assessed.  2 
 3 
Additional sequential experiment 4 
An additional experiment was conducted in 20 participants (mean age 22.7, standard deviation 5 
3.0 years; 11 females) all non-selectively derived from the main cohort of participants to assess 6 
whether timing of the CS with respect to the TS influences CIM-itch response. In this experiment 7 
the exact same stimuli of the CIM-itch condition were applied, but an intermission was held 8 
between the itch CS and the second TS so as to make the paradigm sequential (CIM-itchsequential) 9 
rather than simultaneous. Other procedures of the main experiment, e.g., familiarization 10 
procedures and STI assessment were also conducted to obtain as much similarity as possible. 11 
Timing of the second TS was based on the participant’s CS itch score, rated on the same 12 
electronic VAS as previously described. The investigator checked the VAS every 30 s after the 13 
histamine SPT and the TS was re-applied when the VAS itch was <10 (/100), after a minimum 14 
of 4 minutes and before a maximum of 15 minutes. 15 
 16 
Statistical analyses 17 
Descriptive characteristics were calculated in Excel (Microsoft Office 2013, Redmond, WA, 18 
USA) and analyses were conducted in SPSS version 24 (IBM Corporation, Armonk, NY, USA). 19 
The sample size calculation was performed based on previously obtained test-retest reliability 20 
data for the TS 34. A α-level of 0.05, a power of 0.8 and smallest relevant difference of 30% were 21 
applied using methodology for paired study designs previously outlined 28,41. Calculation of the 22 
variables included averaging the continuous VAS scores within each TS. For mechanical 23 
stimulation, a mean NRS score was calculated for itch by averaging the three STI assessments 24 
and for pain by averaging the 9 MPS assessments at each time point (i.e. at baseline and after 25 
each TS). In addition, a grand average was calculated for all NRS scores after the baseline TS for 26 
itch (STI) and pain (MPS) separately. As measure of CIM and CPM efficacy, for each CS the 27 
itch and pain reduction was calculated by the formula CIM/CPM-efficacy = MEAN VASTS+CS – 28 
MEAN VASTS. When VAS scores were missing for a baseline TS (n=1, for one condition only), 29 
the average VASs of the TSs in the same modality was taken according to the last-observation 30 
carried forward method. Other missing data (e.g., for mechanical stimuli) were handled by 31 
pairwise deletion. In addition to the two non-responders, one participant was unable to complete 32 
any of the CPTs (immersion times were all <30 s). Therefore all data of this participant were 33 
omitted from the statistical analyses, which were performed on 25 participants. Data variables 34 
were checked for normal distribution by standardized skewness and kurtosis values and potential 35 
outliers (> 3 standard deviations from the group mean39). Some variables were not normally 36 
distributed because of an outlier (i.e. mean VAS pain during the CPM-itch condition, the peak 37 
VAS itch during the CIM-itch condition, CPM-efficacy by itch CS). Excluding the outlier 38 
resulted in normal distribution and the analyses were rerun. However, for the variable peak pain 39 
for CPM-itch both an LN-transformation and removing an outlier were necessary to obtain 40 
10 
 
normal distribution. Data that includes the outliers were reported since outliers did not change 1 
the outcome and interpretation in term of the levels of statistical significance (p < 0.05). 2 
 3 
Four repeated measures analyses of variance (RM-ANOVAs) were conducted, two for itch 4 
(primary outcome: mean VAS scores and secondary outcome peak VAS scores) and two for pain 5 
(mean and peak VAS scores). For itch, the RM-ANOVA was constructed with the factors 6 
conditioning stimulation (TS and TS + CS) x condition (CIM-itch, CIM-pain, and CIM-painipsi), 7 
while for pain, the test was constructed with conditioning stimulation (TS and TS + CS) x 8 
condition (CPM-pain and CPM-itch). Moreover, as reliability measure for the TSs before the CS, 9 
two-way random consistency model (2,1) intra-class coefficients (ICCs) were calculated for the 10 
mean VAS itch for the three baseline TSs for itch and for the mean VAS pain for the two 11 
baseline TSs for pain (i.e. intra-individual variability of the primary outcome parameter). Post 12 
hoc paired t-tests were performed for the additional CIM-itchsequential condition in which the mean 13 
and peak VAS itch for the baseline TS compared with the TS after CS were compared. For 14 
exploring the effect of the conditioning stimuli on mechanical dysesthesia, comparable RM-15 
ANOVAs were carried out with the NRS itch evoked with conditioning stimulation (STI/MPS 16 
applied after the TS and after the TS + CS) x condition (all CIM/CPM conditions, respectively). 17 
Additionally, in order to explore the effect of electrical stimulation on mechanical dysesthesia 18 
(irrespective of conditioning stimulation), two additional RM-ANOVAs, one for itch and one for 19 
pain, were conducted comparing baseline NRS with NRS after the baseline TSs. Mauchly’s test 20 
of sphericity was applied for the analyses and in cases where sphericity was violated the 21 
Greenhouse-Geisser corrected p-values were used. The Sidak-Holm correction was applied for 22 
all RM-ANOVAs when performing post hoc tests. While the study was not designed to detect 23 
gender differences an exploratory RM-ANOVA with gender as a between-subjects-variable was 24 
conducted for the outcomes of CIM and CPM efficacy. To address the possibility of biases 25 
related the randomized order of which tests were conducted (i.e. carry-over inhibitory or 26 
facilitatory effects from test or conditioning stimuli), two methods were applied: 1) The orders of 27 
the five conditions were dichotomized by arranging subjects by those whom were subjected to 28 
the itch conditions (1, 2 and 3) first and the pain conditions (4 and 5, see Table 1) secondly, as 29 
well as vice versa. This was then added as a between-subjects factor in the main RM-ANOVA 30 
(two levels: “itch first” or “pain first”), 2) All VAS data in response to electrical stimuli 31 
conducted first were pooled as well as those conducted secondly etc., and thereafter compared 32 
with a one-way ANOVA. This approach would detect potential adaptation or sensitization to the 33 
stimuli per se. Pearson correlation coefficients were calculated across all CIM and CPM efficacy 34 
measures (uncorrected). Moreover, total scores of the self-report questionnaires were 35 
exploratively correlated with the CIM- and CPM-efficacy measures in each of the five conditions 36 
separately using Pearson’s correlation coefficients (uncorrected). Unless stated otherwise, data is 37 
presented as arithmetic means ± standard error of the mean (SEM). A p-value < 0.05 was 38 





Validation of applied test and conditioning stimuli 2 
The baseline electrical itch test stimuli of the three CIM conditions (Fig. 3a) induced, on average, 3 
moderate levels of itch with significantly less concurrent pain (t(24) = -8.70, p < 0.001), while 4 
the baseline electrical pain test stimuli of the two CPM-conditions (Fig. 3b) produced, on 5 
average, more pain than itch (t(24) = 3.59, p = 0.001). The electrical itch test stimuli 6 
predominantly induced itch, while concomitant levels of pain were low (≤ VAS 5/100) in 19/26 7 
participants. The overall induced “itch vs. pain”-percentage was 87% (i.e. 87% of the mean 8 
ratings were perceived as itch and 23% as pain). The electrical pain stimuli predominantly 9 
induced pain with the “pain vs. itch”-percentage being 68%. Similarly, the CS (Fig. 3c) for itch 10 
(histamine) induced more itch than pain (t(24) = 27.31, p < 0.001), while the CS for pain (CPT) 11 
induced more pain than itch (t(24) = 4.08, p < 0.001).  12 
 13 
  14 
<Insert Figure 3 about here>  15 
 16 
Conditioned modulation of itch 17 
 18 
Mean itch scores: For mean VAS itch evoked by the TSs in the CIM conditions (see Fig. 4a, b, 19 
c, and f), the RM-ANOVA showed a significant conditioning stimulation x condition interaction 20 
(F(2,48) = 20.56, p < 0.001). Post hoc Sidak corrected tests showed significantly lower VAS itch 21 
for TSs during CS than for the baseline TS in the CIM-pain (14.1 ± 1.7 versus 6.4 ± 1.1; p < 22 
0.001) and the CIM-painipsi condition (14.8 ± 1.9 versus 4.8 ± 0.9; p < 0.001). There was no 23 
significant modulation effect in the CIM-itch condition, although an insignificant trend was 24 
observed (13.8 ± 1.7 versus 12.1 ± 1.5; p = 0.063). There were no significant differences in mean 25 
VAS itch (primary outcome parameter) between the baseline TSs (all p > 0.661) and the ICC 26 
(2,1) for the three VAS itch TSs ratings at baseline was 0.81. VAS itch for the TSs applied 27 
during CS was significantly lower in both the CIM-pain and CIM-painipsi conditions when 28 
compared to the CIM-itch condition (mean difference -5.7 ± 1.0, p < 0.001 and -7.3 ± 1.1, p < 29 
0.001, respectively). The CIM-pain and CIM-painipsi condition did not significantly differ, 30 
although there was a tendency towards lower VAS itch for the TSs applied during CS in the 31 
latter than in the former condition (mean difference -1.6 ± 0.7, p < 0.096).  32 
Peak itch scores: The peak VAS itch evoked by the TSs in the CIM conditions, RM-ANOVA 33 
also showed a significant conditioning stimulation x condition interaction (F(2,48) = 17.66, p< 34 
0.001). Post hoc Sidak corrected tests showed significantly lower peak VAS itch for TSs during 35 
CS than for the baseline TS in the CIM-itch (33.8 ± 4.0 versus 30.1 ± 3.9; p = 0.048), the CIM-36 
pain (33.7 ± 4.0 versus 17.9 ± 2.9; p < 0.001), and the CIM-painipsi (36.1 ± 4.4 versus 15.1 ± 2.7; 37 
p < 0.001) condition. There were no significant differences in peak VAS itch between the 38 
baseline TSs (all p > 0.440). Peak VAS itch for the TSs applied during CS was significantly 39 
lower in both the CIM-pain and CIM-painipsi conditions when compared to the CIM-itch 40 
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condition (mean difference -12.2 ± 2.5, p < 0.001 and -15.0 ± 2.9, p < 0.001, respectively). The 1 
CIM-pain and CIM-painipsi condition did not significantly differ (p = 0.409).  2 
 3 
 4 
Conditioned modulation of pain 5 
 6 
Mean pain scores: For mean VAS pain evoked by the TSs in the CPM conditions (see Fig. 4d, e 7 
and g), the RM-ANOVA showed a significant conditioning stimulation x condition interaction 8 
(F(1,24) = 6.16, p < 0.020). Post hoc Sidak tests showed significantly lower VAS pain scores for 9 
the TSs during CS than for the baseline TSs in the CPM-pain condition (21.0 ± 2.3 versus 14.8 ± 10 
2.3; p < 0.001), and there was no significant CPM effect in the CPM-itch condition, although an 11 
insignificant tendency was observed (19.4 ± 2.1 versus 17.5 ± 2.0; p = 0.056). The VAS pain 12 
evoked by the baseline TSs did not significantly differ (p = 0.161) and the ICC (2,1) between the 13 
two baseline TSs was 0.92. VAS pain for the TSs applied during CS was not significantly 14 
different between both CPM conditions, although an insignificant tendency was observed for 15 
lower VAS pain for the TSs applied during CS in the CPM-pain than in the CPM-itch condition 16 
(mean difference -2.6 ± 1.5, p = 0.097).  17 
 18 
Peak pain scores: For peak VAS pain evoked by the TSs in the CPM conditions, the RM-19 
ANOVA also showed a significant conditioning stimulation x condition interaction (F(1,24) = 20 
11.28, p = 0.003). Post hoc Sidak corrected tests showed significantly lower VAS pain scores for 21 
the TSs during CS than for the baseline TSs in the CPM-pain condition (54.9 ± 4.9 versus 42.8 ± 22 
5.2; p < 0.001), and there was no significant CPM effect in the CPM-itch condition (52.0 ± 5.1 23 
versus 50.8 ± 5.0; p = 0.626). Peak VAS pain evoked by the baseline TSs did not significantly 24 
differ (p = 0.161). Peak VAS pain for the TSs applied during CS was significantly lower in the 25 
CPM-pain than the CPM-itch condition (mean difference -8.0 ± 3.0, p = 0.015).  26 
 27 
 28 
<Insert Figure 4 about here> 29 
 30 
 31 
Mechanical itch stimulation 32 
STI exhibited a significant increase from 1. 2 ± 0.2 (NRS0-10) at baseline to an average of 1.8 ± 33 
0.3 following the baseline electrical test stimuli for itch (t(23) = 2.15 p = 0.042), signifying that 34 
electrical itch stimulation evoked punctuate hyperknesis (Fig. 5a). The RM-ANOVA showed a 35 
main effect of condition (F(2,46) = 6.02, p = 0.005), with the post hoc test showing average STI-36 
scores to be significantly higher in the CIM-itch (1.8 ± 0.3) than in the CIM-painipsi condition 37 
(1.4 ± 0.2, p = 0.017). A main effect of conditioning stimulation was also present (F(1,23) = 38 
11.78, p = 0.002) and post hoc tests showed STI during TS + CS to be significantly lower than 39 
during baseline TS (p = 0.002), signifying that the conditioning stimuli reduced development of 40 
13 
 
punctuate hyperknesis. The interaction term conditioning stimulation x condition was not 1 
significant, although a trend was observed (F(2,46) = 3.02, p = 0.058).  2 
 3 
Mechanical pain stimulation 4 
MPS did not significantly increase following the baseline electrical test stimuli for pain (t(23) = 5 
1.10 p = 0.284), indicating that the applied electrical stimuli ramps did not evoke cutaneous 6 
mechanical hyperalgesia (Fig. 5b). The RM-ANOVA did not show a significant main effect for 7 
condition (p = 0.263), and only a insignificant trend was observed for conditioning stimulation 8 
(F(1,23) = 3.66, p = 0.068) with average MPS being decreased when comparing scores following 9 
baseline TS (1.9 ± 0.2) to those following application of TS + CS (1.7 ± 0.2). The condition x 10 
conditioning stimulation interaction was not significant (F(1,23) = 0.22, p = 0.642).  11 
 12 
Correlational analyses 13 
The intercorrelations for the CIM and CPM efficacy (uncorrected) were significant between 14 
CIM-itch and CIM-pain (r = 0.52, p = 0.008), between CIM-painipsi and CIM-pain (r = 0.65, p< 15 
0.001) as well as CPM-pain (r = 0.42, p= 0.039), and between CIM-pain and CPM-pain (r = 0.44, 16 
p = 0.028). The remaining correlation coefficients (uncorrected) were not significant. The self-17 
report questionnaire outcomes for catastrophizing (PCS: 16.5 ± 1.7 and PCS-Itch: 17.2 ± 1.5), 18 
psychological distress (HADS-anxiety: 14.8 ± 0.6 and HADS-depression: 17.8 ± 0.5), and 19 
optimism (LOT-r: 16.5 ± 0.8) were not significantly correlated with CIM- and CPM-efficacy in 20 
any of the conditions, except for one significant correlation between more optimism and higher 21 
CPM-efficacy by itch CS (r = 0.47, p = 0.021; after removing the outlier in the CPM-itch 22 
condition). 23 
 24 
Carry-over effects between conditions and gender differences of CIM and CPM efficacy 25 
For both applied carry-over analysis methods outlined in statistical analyses no significant biases 26 
were detected in relation to the order of which the five different paradigms were performed (p ≥ 27 
0.315). The exploratory RM-ANOVA conducted to detect potential gender differences in the 28 
CIM and CPM efficacy did not show any significant gender-related differences neither as an 29 
overall main effect of gender (F(1,23) = 2.81, p = 0.107) nor as a significant condition x gender 30 
interaction (F(4,92) = 0.98, p = 0.425).  31 
 32 
Additional sequential condition with histamine CS 33 
In the sequential CIM-itch condition, the NRS itch evoked by histamine was on average 4.5 ± 34 
2.0 over a mean time of 9.4 ± 3.0 min (range 4.2 – 15.0). The mean VASs itch evoked by the TS 35 
before and after the CS were 11.7 ± 1.7 and 15.2 ± 2.8 respectively, and were not significantly 36 
different (t(19) = 1.61, p = 0.123). The peak VASs itch were on average 31.8 ± 4.1 and 35.2 ± 37 






This study showed that itch could be decreased significantly by simultaneous application of a 2 
heterotopically located painful stimulus similarly to what has been shown for the standard CPM-3 
paradigm (pain-inhibits-pain). Conversely, no itch-inhibitory effect of conditioning heterotopic 4 
itch (CIM-itch) as reflected on the mean itch ratings, was observed. The peak itch intensity only 5 
displayed a comparatively small itch-inhibitory effect by heterotopically applied itch. An 6 
additional experiment where the CIM-itch paradigm was conducted in a sequential manner (in 7 
accordance with two previous studies33,34) also failed to detect a significant CIM-effect from an 8 
itch CS.  9 
 10 
Conditioning pain and itch stimuli 11 
The CPT using 8°C circulating water effectively and consistently produced moderate to high 12 
intensities of pain, and barely any to no itch at all, in accordance with several previous studies 13 
applying and validating this test67,68. Similarly, 1% histamine introduced by skin pricks reliably 14 
produced itch to a moderate extent and low levels of pain, which is in accordance with several 15 
papers utilizing and validating this method7,13. This indicates highly specific induction of pain 16 
and itch by the conditioning stimuli. No adverse reactions were associated with neither the CPT 17 
nor the SPT procedure. Only a single subject was unable to endure the 2-minute CPT. 18 
 19 
Modality specificity and validation of applied experimental test stimuli 20 
The electrical pain and itch stimuli predominantly induced the intended sensation as reflected by 21 
the “pain vs. itch” and “itch vs. pain” percentages. Mild itch was particularly observed prior to 22 
the onset of pain (at ≥ 2.9 mA pain became dominant), indicating that preferential stimulation of 23 
pruriceptive nociceptors occur at a sub-painful level (Fig. 3b). This is in line with previous 24 
observations of a significant positive correlation between itch and pain induced by cowhage 25 
spicules37,62 indicating that the sensations are not unconditionally mutually exclusive. While peak 26 
itch scores were slightly lower than those achieved for electrically induced pain, they were on 27 
par with both previous studies using a similar stimulation methodology, although these studies 28 
assessed the evoked itch intensity retrospectively and ramped up only to 5 mA9,34. Notably the 29 
achieved peak itch intensity and the itch purity were comparable to most standardized chemical 30 
itch provocations, e.g., histamine iontophoresis/SPT or cowhage application5,7,34. In this relation, 31 
the present study did screen out participants not responsive to both the itch and pain induction 32 
paradigms (2 participants were excluded). Lastly, it is conceivable that slightly higher electrical 33 
currents could have evoked more intense itch, but as indicated by stimulus-response curve 34 
flattening at high intensities (e.g., Fig. 3a), itch would likely increase only marginally with 35 
concomitant increases in pain as shown in earlier studies on electrically induced itch10,24,60,65. 36 
This highlights the sparsely articulated conundrum of the contrasting outcomes resulting from 37 
increasing pain and itch stimulation intensities (of various modalities), i.e. resulting in reaching 38 




Conditioned modulation of itch and pain 1 
The magnitude of the decrease found in the standard CPM-paradigm (pain inhibits pain) 2 
conducted as a “positive control” is in line with results from numerous previous studies using the 3 
CPT or deep somatic stimulation as the CS 26,66,68,70. The paradigm in which a conditioning itch 4 
stimulus was applied together with a contralateral pain TS (CPM-itch) conducted as a “negative 5 
control”, did not produce a significant decrease, although a trend towards a small decrease was 6 
evident, perhaps related to itch-induced distraction. Statistical analyses of a potential order or 7 
“carry-over” effect between the conditions did not yield significant findings indicating that 10-8 
minute breaks were sufficient to avoid significant carry-over interference as also suggested by a 9 
previous study26.  10 
Itch levels were on average not significantly affected by conditioning itch stimulation (CIM-itch, 11 
Fig. 4a), although a tendency towards a small decrease was observed. Notably, a comparatively 12 
small (≈ 9% reduction from baseline) but significant decrease following CIM-itch was observed 13 
for the peak itch indicating that there could be minor inhibitory effect in the higher range of the 14 
TS ramp. These findings are in opposition to two previous studies detecting a significant itch-15 
evoked CIM-effect32,34. These studies both used iontophoretically delivered histamine as the CS 16 
and electrically induced itch as TS conducted with a comparable stimulation paradigm, although 17 
the intensity was tailored to each individual participant, resulting in an overall lower electrical 18 
current being applied. In these previous studies, the test and conditioning stimuli were delivered 19 
in a sequential manner,32,34 opposed to the simultaneous approach used in the main experiment of 20 
the present study. However, the present additional experiment with a sequential design also 21 
failed to detect a significant modulation of itch following conditioned itch stimulation. The 22 
explanation for the discrepancy in results may lie in differential methodology, but as the present 23 
study used both more intense conditioning and test stimuli than both previous studies, larger 24 
decreases were expected in line with what is known from CPM studies21,43. Whether, and the 25 
extent to which, there is a modulation effect of itch by conditioning itch stimulation should be 26 
investigated further. In contrast, itch levels were prominently reduced by conditioning pain 27 
stimuli (Fig. 4b and 4c). The itch-inhibitory effect of distantly located pain stimulation has 28 
previously been assessed thrice using the CPT or deep-somatic cuff-algometric stimulation as 29 
conditioning stimuli3,34,42. The findings of the present study, i.e. a reduction of itch during contra-30 
/ipsilateral conditioning pain stimulation, are well in line with previous findings of pain 31 
modulation when applying the CPT21,43. However, deep somatic conditioning pain stimulation 32 
has previously been found not to modulate histaminergic itch3. This discrepancy is likely related 33 
to tissue-preferentiality of the CPM-effect, i.e., several studies found no effect of deep somatic 34 
conditioning pain on painful cutaneous test stimuli, while it was highly effective in reducing pain 35 
arising from musculoskeletal test stimuli.26,29,44 The exploratory analysis of gender-related 36 
effects did not reveal any significant differences for CIM and CPM efficacy between males and 37 
females. Previous studies suggest a fairly consistent pattern of results, with females exhibiting 38 
enhanced pain sensitivity, increased pain facilitation as well as reduced endogenous pain 39 
inhibition compared with males.30,52 However, meta analyses of studies on gender differences in 40 
16 
 
pain sensitivity has repeatedly voiced concerns regarding underpowered studies.19,54 The present 1 
study was not a priori powered nor designed to detect gender differences, so this exploratory 2 
analysis should be interpreted with caution.  3 
While previous studies suggest C-fibers as the probable substrate for electrically induced itch 4 
24,40 it is unclear whether the applied test stimuli neurophysiologically mimics itch observed in, 5 
patients with chronic itch and as such extrapolation should be made with care. However, a 6 
previous study using cowhage as test stimulus, in combination with the CPT, found similar 7 
reductions of itch to those we observed, indicating that the itch test-stimulus is not highly 8 
modality-dependent 42. Along these lines, histamine as a conditioning itch stimulus has only been 9 
incidentally tested 32,34 and since cowhage is generally capable of inducing significantly more 10 
severe itch than histamine 2,5,47, it could potentially be better suited as conditioning stimulation. 11 
Here however it should be noted that cowhage is a less “pure” pruritogen than histamine in that it 12 
also evokes more coinciding pricking/stinging pain 2,61,62. This could potentially make it unclear 13 
whether a potential modulatory effect is in fact related to the evoked itch or the evoked pain. 14 
Collectively, these findings may suggest that pain and itch, as somatosensory modalities, are 15 
under hierarchical prioritization in a manner promoting perception of pain whenever both 16 
sensations are heterotopically presented in a simultaneous manner. This has previously been 17 
established and mechanistically explored for homotopically applied itch and pain, where painful 18 
counter-stimuli generally prominently inhibit itch,6,27,71 but this study is the first to systematically 19 
elucidate such sensory prioritization for heterotopically applied itch and pain stimuli. In this 20 
context it should be highlighted that although a high CPT temperature (8°C) was used, higher 21 
effective conditioning intensity scores were achieved for pain conditioning than for itch. While 22 
this could lead to a relative overestimation of the efficacy of pain-induced descending inhibition, 23 
a previous study suggests that a ceiling effect in the CPM-effect is reached when increasing the 24 
conditioning pain intensity from mild, i.e. VAS ≈ 30 (well below the herein achieved 25 
conditioning itch intensity), to moderate, i.e. VAS ≈ 60 (VAS0-100) 21,43. This is in line with 26 
recent CPM consensus recommendations68 and would infer that in terms of achieved intensity, 27 
the presently applied itch and pain conditioning stimuli have comparable inhibitory capacity. 28 
Moreover, while no studies assessing the affect of the intensity of conditioning itch stimulation 29 
in CIM paradigms exist, previous findings suggest that a CIM-effect is achievable a lower itch 30 
intensities than herein applied 32,34. 31 
 32 
Role of individual characteristics 33 
Catastrophizing, optimism and psychological distress did, in contrast to some previous 34 
indications for pain 17,22, not seem to play a significant role (only one correlation coefficient out 35 
of multiple, uncorrected tests was significant) in the itch and pain modulation in healthy humans. 36 
Although internal consistency was good, non-significant associations of the catastrophizing scale 37 
modified for itch should be interpreted with caution since this adjusted scale has not previously 38 




Elicitation and modulation of dysesthesias  2 
STI significantly increased following electrical itch stimuli, indicative primarily of hyperknesis 3 
rather than alloknesis, because the majority of participants reported itch in response to the von 4 
Frey probing at baseline and because of the punctuate character of the applied stimuli. However, 5 
the modest absolute increases observed for mechanically evoked itch combined with substantial 6 
variability limit clinical relevance for the applied induction and/or assessment technique. 7 
Hyperknesis, as well as alloknesis, have previously been reported following electrically evoked 8 
itch24 and following chemical itch provocations when using the same assessment technique as 9 
the present study2. Mechanistically, hyperknesis is thought to perceptually reflect centrally-10 
mediated sensitization of Aδ- or polymodal C-nociceptor2,24,35, enabling increased itch in 11 
response to pricking and mildly itching mechanical stimuli. Conditioning stimulation caused a 12 
significant decrease in STI, signifying that this sensitization was partly inhibited by concomitant 13 
conditioning itch or pain stimuli. Notably, an insignificant trend was observed on the interaction 14 
term indicating that STI was reduced most prominently in the CIM-pain and CIM-painipsi 15 
conditions. MPS was not significantly altered by the painful electrical stimulation, indicating that 16 
the paradigm did not cause cutaneous mechanical hyperalgesia. Contralateral pain and itch 17 
conditioning stimulation did not alter MPS, which is partly in line with a previous study 18 
assessing the effect of conditioning pain stimulation of pinprick-evoked pain sensitivity44.  19 
 20 
Conclusion 21 
In summary the present study showed that while conditioning pain stimulation effectively induce 22 
inhibition of both concurrent pain as well as itch, conditioning itch stimulation does not elicit a 23 
reduction of concurrent pain nor itch, although a small decrease was observed when specifically 24 
assessing peak itch responses. Conditioning itch stimulation is likely insufficient to evoke robust 25 
descending inhibition.  26 
 27 
Perspective 28 
Provided that an itch-evoked CIM-effect exists, its physiological role, and consequently its 29 
clinical relevance seem limited, given that it cannot be robustly elicited under controlled 30 
conditions. On the other hand, the endogenous inhibitory system activated by painful stimulation 31 
inhibited itch to at least the same extent as painful test stimuli. The significant associations 32 
between itch modulation by itch and pain conditioning as well as CPM efficacy by painful 33 
conditioning stimulation indicates involvement of a shared inhibitory system, which is most 34 
effective with painful conditioning stimulation. As such, pain-induced endogenous modulation of 35 
itch seems to be a better measure of one’s itch modulatory capacity than itch-evoked CIM. 36 
Aligned with previous studies showing reduced CPM-efficacy in patients with chronic itch28,49, 37 
less efficacious itch modulation by pain may be involved in the pathophysiology of chronic itch. 38 
This is supported by previous findings that patients with chronic itch require more intense 39 
homotopic noxious counter-stimulation to achieve itch-relief compared to healthy controls27. As 40 
18 
 
such, future research on the inhibitory efficacy of conditioning pain stimuli on both pain and itch 1 
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 Figures/tables 1 
 2 
Table 1: Overview of the different conditioned itch modulation (CIM) and conditioned pain 3 
modulation (CPM) conditions as well as assessed mechanical dysesthesias pertaining to each 4 
condition. 5 
 6 
  7 
Condition Test stimuli Conditioning stimulation  Assessment of 
dysesthesia  
1. CIM-itch Electrical itch 
test stimuli 
Contralateral conditioning itch 
stimulation with histamine 
Sensitivity to touch evoked 
itch with von Frey 
monofilaments 
2. CIM-pain Electrical itch 
test stimuli 
Contralateral conditioning pain 
stimulation with the cold 
pressor task 
Sensitivity to touch evoked 






Ipsilateral conditioning pain 
stimulation with the cold 
pressor task 
Sensitivity to touch evoked 






Contralateral conditioning pain 
stimulation with the cold 
pressor task 
Mechanical pain 
sensitivity using pinprick 
stimulators  
5. CPM-itch Electrical pain 
test stimuli 
Contralateral conditioning itch 
stimulation with histamine 
Mechanical pain 






Figure 1: Time line of the experiment. IC: informed consent; CIM: conditioned itch 3 
modulation; CPM: conditioned pain modulation; TS: test stimulus; CS: conditioning stimulus. 4 
Note: within each CIM/CPM condition, also mechanical stimulation was applied after each TS. 5 
 6 




Figure 2: Application sites for somatosensory stimuli. The side (left/right) on which the 2 
electrically evoked itch and pain test stimuli were applied was randomized. Consequently, the 3 
conditioning stimuli for itch (histamine skin prick) and pain (cold pressor task) as well as the 4 
dysesthesia assessments for itch (Von Frey monofilaments) and pain (mechanical pinprick 5 
stimulators) were applied accordingly. SPT: skin prick test. 6 
 7 




Figure 3: Selectivity and intensity of itch and pain induced by test- and conditioning 2 
stimulation. a) Average itch and pain induced by all itch test stimuli, i.e. average itch and pain 3 
ratings for the test stimuli within the experimental itch and pain conditions, b) Average itch and 4 
pain induced by all pain test stimuli. Notice that for a and b the electrical test stimulus paradigms 5 
quite selectively induced itch and pain, respectively, c) Average itch and pain induced by 6 
histamine provocations and cold pressor tasks. CIM: conditioned itch modulation; CPM: 7 
conditioned pain modulation, CS: conditioning stimulus; mA: miliAmpère; NRS: Numeric rating 8 
scale; VAS: Visual analogue scale. ** = p < 0.01.  9 
 10 






Figure 4: Modulation of electrically induced itch and pain by conditioning itch and pain 1 
stimulation displayed as stimulus response curves (a-e) and with the itch and pain ratings 2 
averaged over the stimulation period (f-g). Specifically displayed in a) Itch during itch as CS – 3 
1. “CIM-itch”, b) Itch during pain as CS (contralaterally) – 2. “CIM-pain”, c) Itch during pain as 4 
CS (ipsilaterally) – 3. “CIM-painipsi”, d) Pain during pain as CS (contralaterally) – 4. “CPM-5 
pain”, e) Pain during pain as CS (contralaterally) – 5. “CPM-itch”, f) Mean itch intensities within 6 
each condition g) Mean pain intensities within each condition. CIM: Conditioned itch 7 
modulation; CPM: Conditioned pain modulation, CS: Conditioning stimulus; mA: miliAmpère; 8 
NRS: Numeric rating scale; TS: Test stimulus; VAS: Visual analogue scale. * = p < 0.05, ** = p 9 
< 0.01.  10 
 11 
  12 
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Figure 5: Assessment of 1 
mechanical hyperknesis and hyperalgesia. a) Sensitivity to touch evoked itch (STI) before TS 2 
(dotted line), after TS (white bars), and after TS and CS (grey bars) for each CIM condition, b) 3 
Mechanical pain sensitivity (MPS) before (dotted line), after TS, and after TS and CS for each 4 
CPM condition. CIM: Conditioned itch modulation; CPM: Conditioned pain modulation, CS: 5 
Conditioning stimulus; NRS: Numeric rating scale; TS: Test stimulus. */# = p < 0.05, ** = p < 6 
0.01, * indicates difference from baseline STI, # indicates difference for the main effect of 7 
condition.  8 
9 
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